Human C1-Esterase Inhibitor Csl Behring (C1 Esterase Inhibitor (Human))

Human C1‑Esterase Inhibitor Csl Behring is indicated for the treatment and prevention of angioedema episodes caused by C1‑esterase inhibitor deficiency.

• Hereditary angioedema type I (C1‑inhibitor deficiency)
• Hereditary angioedema type II (C1‑inhibitor dysfunction)
• Acquired angioedema associated with C1‑inhibitor consumption
• Short‑term prophylaxis of angioedema attacks before medical or dental procedures
• Adjunct therapy for patients who do not respond adequately to other C1‑inhibitor products

• Human C1‑Esterase Inhibitor replaces the missing or dysfunctional C1‑inhibitor protein in the plasma. By binding to and inactivating C1‑esterase, factor XIIa, and plasma kallikrein, it suppresses uncontrolled activation of the complement cascade and the kallikrein‑kinin system. This reduces generation of bradykinin, the mediator responsible for increased vascular permeability and swelling during angioedema attacks. Restoring normal inhibition helps maintain vascular homeostasis and prevents the rapid onset of edema.

Adverse reactions to Human C1‑Esterase Inhibitor are generally related to the infusion process or immune response to the protein.

Common

• Injection site erythema or pain
• Transient headache
• Nausea or mild gastrointestinal discomfort
• Low‑grade fever

Serious

• Anaphylactic or severe hypersensitivity reactions
• Thromboembolic events such as deep‑vein thrombosis
• Acute renal impairment
• Severe hypertension or hypotension

Before using Human C1‑Esterase Inhibitor, clinicians should evaluate patient history and monitor for specific safety concerns.

• Assess for known hypersensitivity to human plasma proteins or any component of the formulation.
• Use caution in patients with a history of thromboembolic disease or cardiovascular risk factors.
• Monitor vital signs and for signs of anaphylaxis during and after infusion.
• Adjust dosing in patients with severe renal or hepatic impairment as recommended by the prescribing information.
• Avoid use in pregnant or nursing women unless the potential benefit justifies the risk, as safety data are limited.

Human C1‑Esterase Inhibitor may interact with other medications that affect coagulation, immune response, or complement pathways.

Avoid

• Concomitant use of other plasma‑derived products that contain C1‑inhibitor, which may increase the risk of immune complex formation.
• High‑dose anticoagulants (e.g., warfarin, direct oral anticoagulants) that could exacerbate bleeding tendencies when combined with infusion‑related vascular changes.

Use with caution

• ACE inhibitors or angiotensin receptor blockers, as they can also increase bradykinin levels.
• Immunosuppressive agents that may mask signs of hypersensitivity reactions.
• Diuretics or antihypertensive drugs, requiring close monitoring of blood pressure during infusion.
• Other biologic therapies, where additive immunogenicity could occur.